Delivery Order SPE2DB20D1100-SPE2DB23FD8F8
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $19,410.94, is a delivery order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 30, 2024 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,750.80 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The contract is a Delivery Order with a Firm Fixed Price of $25,335.45 and a period of performance through November 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,988.66 firm fixed-price delivery order is for Pulmozyme 1 mg/mL ampules (2.5 mL) and has a completion date of November 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a broad range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office division. The $33,136.24 firm-fixed-price delivery order is for the supply of Pulmozyme 1 mg/mL ampuls (2.5 mL). The contract has an ultimate completion date of August 9, 2024 and does not utilize a set-aside. Amerisourcebergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies,...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract worth $77,882.80 to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of August 18, 2022. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,001.35, is for the delivery of Pulmozyme 1 mg/ml ampuls with a 2.5 ml dosage. The contract has a completion date of February 16, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a federal contract award to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $10,995.34 delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a respiratory medication, with a completion date of September 10, 2024. This contract is not set aside and is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999 through December 2025...
- The U.S. Defense Logistics Agency (DLA) awarded a $71,709.80 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 4,566,915,634 units of the drug Pulmozyme, which is used for the treatment of cystic fibrosis. The contract has an ultimate completion date of January 14, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,740.65 firm fixed-price delivery order is for the supply of Pulmozyme, a medication used to treat cystic fibrosis. The contract has an ultimate completion date of July 10, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB23FD8F8Delivery Order
This federal contract award, with ID SPE2DB20D1100|SPE2DB23FD8F8, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $63,169.88 firm fixed-price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, to support federal healthcare programs. The contract has an ultimate completion date of September 26, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, the company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $63.2k | 9/25/23 |